Although further studies are needed, including identification of iMDK direct targets, additional structural modification and safety validation, iMDK looks to be a promising treatment for KRAS mutant pulmonary adenocarcinoma and squamous cell carcinoma and possibly for the treatment of other cancers and chronic inflammatory diseases. The gene discussed is KRAS; the disease is squamous cell carcinoma.